A Precision Approach to Herpes Outbreaks
Q-REStrain is a personalized oligonucleotide infusion designed to inhibit Herpes Simplex Virus replication
Investigational, evidence-emerging
Personalized via lab analysis
Co-managed with your providers
How it works
Confirm HSV
PCR/serology
Create your oligonucleotide infusion
Sequence-specific design tailored to you
Infusion + follow-up
Monitor over 4–6+ months
Is it right for me?
• Frequent outbreaks despite standard care
• Prefer a precision, non-antiviral strategy
• Comfortable with personalized non-FDA approved options
*Not FDA-approved for HSV; evidence is preliminary. We provide detailed, informed consent and coordinate with your primary provider(s).
FAQs
Is this a cure?
Q-REstrain is designed to target viral replication at the genetic level, to reduce outbreak frequency and severity. However, this is not a cure, and outcomes vary between individuals. We work with you to set realistic expectations based on current evidence.
How soon can I receive it?
After eligibility, lab confirmation, and Q-REstrain blood draw, it takes 4-6 weeks to receive the personalized oligonucleotide therapy solution in the clinic.
Do I stop antivirals?
Only with clinician guidance; we co-manage care per CDC best practices.
Note: This investigational treatment uses patient-specific nucleic acid (targeted microRNA) therapy designed to bind defined viral gene sequences and interfere with HSV replication.